Format

Send to

Choose Destination
Neurotherapeutics. 2017 Apr;14(2):265-273. doi: 10.1007/s13311-017-0526-y.

Medulloblastoma: Molecular Classification-Based Personal Therapeutics.

Author information

1
Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA.
2
Harvard Medical School, Boston, MA, 02115, USA.
3
Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA. scott.pomeroy@childrens.harvard.edu.
4
Harvard Medical School, Boston, MA, 02115, USA. scott.pomeroy@childrens.harvard.edu.

Abstract

Recent advances in cancer genomics have revealed 4 distinct subgroups of medulloblastomas, each with unique transcription profiles, DNA alterations and clinical outcome. Molecular classification of medulloblastomas improves predictions of clinical outcome, allowing more accurate matching of intensity of conventional treatments with chemotherapy and radiation to overall prognosis and setting the stage for the introduction of targeted therapies.

KEYWORDS:

DNA methylation; Genomic; Group 3; Group 4; MYC; Medulloblastoma; SHH; Subgroups; WHO; WNT

PMID:
28386677
PMCID:
PMC5398996
DOI:
10.1007/s13311-017-0526-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center